Medical Advancements in Benign Prostatic Hyperplasia Treatments.

IF 2.5 2区医学 Q2 UROLOGY & NEPHROLOGY

Current Urology Reports Pub Date : 2024-05-01 Epub Date: 2024-03-07 DOI:10.1007/s11934-024-01199-4

Vishnuvardhan Ganesan, Deepak Agarwal

{"title":"Medical Advancements in Benign Prostatic Hyperplasia Treatments.","authors":"Vishnuvardhan Ganesan, Deepak Agarwal","doi":"10.1007/s11934-024-01199-4","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia.Recent findings: The latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists. The alpha-blocker + 5-ARI combination remains ideal for enlarged, significantly reducing clinical progression risk compared to monotherapy. Alpha-blocker + PDE5 inhibitor combinations appear safe and potentially beneficial for men with concomitant erectile dysfunction; sildenafil might hold an edge over tadalafil based on limited data. Beta-3 agonists show synergistic effects with alpha blockers for residual storage symptoms, offering similar efficacy to anticholinergics but with a better side effect profile.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":" ","pages":"93-98"},"PeriodicalIF":2.5000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-024-01199-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia.

Recent findings: The latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists. The alpha-blocker + 5-ARI combination remains ideal for enlarged, significantly reducing clinical progression risk compared to monotherapy. Alpha-blocker + PDE5 inhibitor combinations appear safe and potentially beneficial for men with concomitant erectile dysfunction; sildenafil might hold an edge over tadalafil based on limited data. Beta-3 agonists show synergistic effects with alpha blockers for residual storage symptoms, offering similar efficacy to anticholinergics but with a better side effect profile.

查看原文本刊更多论文

良性前列腺增生症治疗的医学进展。

综述目的：本综述旨在确定和总结目前有关治疗良性前列腺增生症引起的下尿路症状的最新治疗药物和组合策略的文献：良性前列腺增生治疗的最新进展在于联合疗法。α受体阻滞剂仍是治疗的主要药物，但研究人员正在探索将其与5-α还原酶抑制剂（5-ARIs）、磷酸二酯酶-5（PDE5）抑制剂和β-3激动剂联合使用的协同作用。与单药治疗相比，α-受体阻滞剂+5-ARI 联合用药仍是肥大的理想选择，可显著降低临床进展风险。α-受体阻滞剂+PDE5抑制剂联合用药似乎是安全的，而且可能对合并勃起功能障碍的男性有益；根据有限的数据，西地那非可能比他达拉非更具优势。β-3激动剂与α受体阻滞剂对残余贮积症状有协同作用，其疗效与抗胆碱能药相似，但副作用更小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Urology Reports UROLOGY & NEPHROLOGY-

CiteScore

4.60

自引率

3.80%

发文量

期刊介绍： This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.